Navigation Links
Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
Date:5/6/2010

PRINCETON, N.J., May 6 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) announced today details of the company's cardiovascular outcomes trial for Victoza® (liraglutide [rDNA origin] injection), which is set to start in the autumn of 2010.

The trial named LEADER™ (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) aims to assess and confirm the cardiovascular safety of the company's new once-daily human GLP-1 analog Victoza®.  The trial satisfies the new FDA guideline for type 2 diabetes treatments.

The protocol of this trial has been designed in close collaboration with an international expert Steering Committee, as well as U.S. and EU regulatory authorities, and with assistance from the Population Health Research Institute (PHRI) at McMasters University, Canada.  Furthermore, an independent Data Monitoring Committee (DMC) will monitor progress of the trial and ensure that it meets the highest standards of ethics and subject safety.

"There is a well-established association between cardiovascular disease (CVD) and type 2 diabetes," says Dr. John Buse, Chief of Endocrinology and Director of the Diabetes Care Center at the University of North Carolina School of Medicine, and Chairman of the LEADER™ Steering Committee.  "In fact, CVD ranks as the major cause of death in diabetes, accounting for 50% of all diabetes fatalities.  As a result there is a serious unmet need for further long-term studies to help assess the risk of CVD in patients with type 2 diabetes."

The vast majority of people with type 2 diabetes suffer from a range of co-morbidities such as ob
'/>"/>

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
2. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
3. Novo Nordisk is Changing Possibilities in Hemophilia
4. Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
5. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
8. Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology
9. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
10. MCNC Partners With Sonic Foundry to Provide Classroom Technology to K-20 Community
11. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... The Journal of Parasitology – Although ... software, it creates questions of ethics. For scientific publications, ... already published case shows, scientific publications need clear guidelines ... Journal of Parasitology features a commentary on ... article published in the Journal of the New York ...
(Date:6/19/2013)... study published in the June 19 online edition of ... by researchers from the University of California, San Diego ... that take place when cardiac regeneration occurs in zebrafish ... that various cell lines in the heart are more ... than previously thought. , More importantly, the research reveals ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
(Date:6/19/2013)... -- Nearly 70 percent of Americans are ... than half take two, Mayo Clinic researchers say. ... prescribed, their study found. Twenty percent of patients ... to the findings, published online in the journal ... For audio and video of Dr. Jennifer St. ...
Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... ... the most widely used resource for consumers looking for a top doctor in their community. ... New York, NY (PRWEB) November 16, 2009 ... many dating sites and search through endless profiles until they find their match. Want to ...
... ... of Trendy Socks for Kids who Wear Ankle-Foot Orthoses (AFOs) , ... Westchester, NY (PRWEB) November 16, 2009 -- Ross ... today its marketplace debut and the launch of “Cool Clothes for Toes,” the first creatively ...
... ... has been selected by Goldline Research as one of the leading Laser ... Laser Eye Surgeons of the United States has been published in the ... vision trials, and originator of LASIK in Denver, Colorado, Dr. Jon Dishler ...
... Nov. 16 Acknowledging that their results are "not ... International Journal of Andrology nevertheless attempt to link reduced masculine ... exposure to phthalates. The researchers, led by Dr. Shanna ... much publicized, study of phthalate exposure to evaluate the play ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... the Company will hold a teleconference and webcast at 8:00 a.m. ... pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial ... , Conference Call and Webcast Information , To ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
Cached Medicine News:Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 2Health News:Ross Daniel Adaptive Apparel Announces Company Debut and 'Cool Clothes for Toes' 3Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: